Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Blood (2024) 144 (23): 2375–2388.

https://doi.org/10.1182/blood.2023023616

Published: 2024

Includes: Supplemental data

Journal Articles

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Blood (2024) 144 (6): 615–628.

https://doi.org/10.1182/blood.2023022823

Published: 2024

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): Complete Follow-up of the Children's Oncology Group (COG) AALL1931 Study

Luke Maese, Mignon L. Loh, Mi Rim Choi, Tong Lin, Etsuko Aoki, Shirali Agarwal, Vijayalakshmi Chandrasekaran, Yali Liang, Suzette Girgis, Cuiping Chen, Robert Iannone, Lewis B. Silverman, Elizabeth A. Raetz, Rachel E. Rau

Blood (2023) 142 (Supplement 1): 1498.

https://doi.org/10.1182/blood-2023-172577

Published: 2023

Journal Articles

MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant

Amrita Y. Krishnan, Salomon Manier, Evangelos Terpos, Saad Usmani, Josephine Khan, Rachel Pearson, Suzette Girgis, Yue Guo, Dana McAleer, Yunsi Olyslager, Tobias Kampfenkel, Niels W.C.J. van de Donk

Blood (2022) 140 (Supplement 1): 10148–10149.

https://doi.org/10.1182/blood-2022-160173

Published: 2022

Journal Articles

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Blood (2022) 140 (Supplement 1): 241–243.

https://doi.org/10.1182/blood-2022-162709

Published: 2022

Journal Articles

Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Blood (2022) 140 (Supplement 1): 4382–4383.

https://doi.org/10.1182/blood-2022-162859

Published: 2022

Journal Articles

Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Marie-Emilie Willemin, Shun Xin Wang Lin, Loeckie De Zwart, Liviawati S. Wu, Xin Miao, Raluca Verona, Arnob Banerjee, Baolian Liu, Rachel Kobos, Ming Qi, Daniele Ouellet, Jenna D. Goldberg, Suzette Girgis

Blood (2022) 140 (Supplement 1): 7253–7254.

https://doi.org/10.1182/blood-2022-162856

Published: 2022

Journal Articles

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Blood (2021) 138 (Supplement 1): 896.

https://doi.org/10.1182/blood-2021-147915

Published: 2021

Journal Articles

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Amrita Y. Krishnan, Monique C. Minnema, Jesús G. Berdeja, Albert Oriol, Niels W.C.J. van de Donk, Paula Rodriguez-Otero, Elham Askari, Maria-Victoria Mateos, Luciano J. Costa, Raluca I. Verona, Xuewen Ma, Suzette Girgis, Shiyi Yang, Brandi W. Hilder, Jeffery Russell, Jenna D. Goldberg, Ajai Chari

Blood (2021) 138 (Supplement 1): 158.

https://doi.org/10.1182/blood-2021-146868

Published: 2021

Journal Articles

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Alfred L. Garfall, MD, Saad Z. Usmani, MDMBBS,MBA, María-Victoria Mateos, Hareth Nahi, MD PhD, Niels W.C.J. van de Donk, MD PhD, Jesus F. San-Miguel, MD PhD, Albert Oriol Rocafiguera, MD, Laura Rosinol, MD PhD, Ajai Chari, MD, Manisha Bhutani, MD, Lixia Pei, PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Tara Stephenson, PhD, Jenna D. Goldberg, MD, Arnob Banerjee, MD, Amrita Krishnan, MD

Blood (2020) 136 (Supplement 1): 27.

https://doi.org/10.1182/blood-2020-138831

Published: 2020

Journal Articles

Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients

Suzette Girgis, PhD BPharm, MS, Shun Xin Wang Lin, PhD, Kodandaram Pillarisetti, MSc, Arnob Banerjee, MD, Jenna D. Goldberg, MD, Shoba Shetty, PhD, Tara Stephenson, PhD, Brandi W. Hilder, PhD, Brett Hanna, Jennifer Smit, Homer Adams III, PhD, Yu-Nien (Tom) Sun, PhD, Jeffrey R. Infante, MD, Yusri A Elsayed, MD PhD, Amarnath Sharma, PhD

Blood (2020) 136 (Supplement 1): 35.

https://doi.org/10.1182/blood-2020-140565

Published: 2020

Journal Articles

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Ajai Chari, MD, Jesus G. Berdeja, MD, Albert Oriol, Niels W. C. J. van de Donk, MD, Paula Rodriguez, Elham Askari, Maria-Victoria Mateos, MD PhD, Monique C. Minnema, MD PhD, Raluca Verona, PhD, Suzette Girgis, PhD BPharm, MS, Thomas Prior, Brandi W. Hilder, PhD, Jeffery Russell, MD PhD, Jenna D. Goldberg, MD, Amrita Krishnan, MD

Blood (2020) 136 (Supplement 1): 40–41.

https://doi.org/10.1182/blood-2020-133873

Published: 2020

Journal Articles

Exploratory Pharmacokinetic/Pharmacodynamic and Tolerability Study of BCMAxCD3 in Cynomolgus Monkeys

Suzette Girgis, PhD BPharm, MS, Shoba Shetty, PhD, Trina Jiao, MS, Chidozie Amuzie, Dan Weinstock, Rebecca Grimme Watson, Joyce Ford, Kodandaram Pillarisetti, Eric Baldwin, Kevin Bellew

Blood (2016) 128 (22): 5668.

https://doi.org/10.1182/blood.V128.22.5668.5668

Published: 2016

Journal Articles

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

Philippe Moreau, MD, Ievgenii I Karamanesht, MD, Natalia Domnikova, Maryna Y Kyselyova, MD, Kateryna Vilchevska, Vadim A Doronin, MD, PhD, Alexander Schmidt, MD, Cyrille Hulin, MD, Xavier Leleu, MD, PhD, Dixie-Lee Esseltine, MD, FRCPC, Karthik Venkatakrishnan, Donna M Skee, BS, Huaibao Feng, PhD, Suzette Girgis, Andrew Z Cakana, MD, FRCPath, William M Deraedt, PhD, Thierry Facon, MD

Blood (2011) 118 (21): 1863.

https://doi.org/10.1182/blood.V118.21.1863.1863

Published: 2011

Journal Articles

Effect of the Cytochrome P450 3A4 Inducers, Rifampicin and Dexamethasone, on the Pharmacokinetic, Pharmacodynamic and Safety Profile of Bortezomib In Patients with Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL)

Andrzej Hellmann, Simon A. Rule, Jan Walewski, Ofer Shpilberg, Huaibao Feng, Helgi van de Velde, Hamina Patel, Donna M Skee, Suzette Girgis, Vernon Louw

Blood (2010) 116 (21): 3983.

https://doi.org/10.1182/blood.V116.21.3983.3983

Published: 2010

NARROW

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies

Correlation of immune fitness with response to teclistamab in relapsed/refractory multiple myeloma in the MajesTEC-1 study

Efficacy and Safety of Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LBL): Complete Follow-up of the Children's Oncology Group (COG) AALL1931 Study

MajesTEC-7: A Phase 3, Randomized Study of Teclistamab + Daratumumab + Lenalidomide (Tec-DR) Versus Daratumumab + Lenalidomide + Dexamethasone (DRd) in Patients with Newly Diagnosed Multiple Myeloma Who Are Either Ineligible or Not Intended for Autologous Stem Cell Transplant

Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC-1

Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma

Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma

Updated Phase 1 Results from MonumenTAL-1: First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma

Updated Phase 1 Results of Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Relapsed and/or Refractory Multiple Myeloma (RRMM)

Translational Approach of Using Ex Vivo Cytotoxicity and Early Clinical Data to Predict Teclistamab Efficacious Therapeutic Range in Multiple Myeloma Patients

A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM)

Exploratory Pharmacokinetic/Pharmacodynamic and Tolerability Study of BCMAxCD3 in Cynomolgus Monkeys

Pharmacokinetics (PK) and Pharmacodynamics (PD) of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients with Relapsed Multiple Myeloma: Effects of Subcutaneous Injection Site and Concentration, and Patient Characteristics

Effect of the Cytochrome P450 3A4 Inducers, Rifampicin and Dexamethasone, on the Pharmacokinetic, Pharmacodynamic and Safety Profile of Bortezomib In Patients with Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only